Navigation Links
Allergic reactions to gadolinium-based contrast agents are rare, study finds
Date:12/28/2007

Allergic-like reactions to gadolinium-containing contrast injections in adults and pediatric patients (those younger than 19 years of age) are rare, according to a recent study conducted by researchers at the University of Michigan Health Systems in Ann Arbor. When these reactions do occur, most of them are mild, said Jonathan R. Dillman, MD, lead author of the study.

Over the past few years, the utilization of contrast-enhanced MRI has markedly increased; its increased by 65% at our institution over the previous five years, said Dr. Dillman.. This is due, at least in part, to a variety of new applications, such as magnetic resonance angiography (MRA) and abdominopelvic MR imaging, he said. Consequently, the number of intravenously administered gadolinium-containing contrast material doses over the same time period has significantly increased. Based on the extensive use these intravascular contrast agents, we felt that it was once again time to study their safety profile, he said.

The study included 78,353 gadolinium-containing contrast injections over a five year period. Acute allergic-like reactions occurred following 54 injections. According to the study, 48 reactions involved adults and six occurred in pediatric patients. The study showed that 74% of these reactions were mild, 19% were moderate, and 7% were severe.

Despite recent concerns that have emerged about the gadolinium-based contrast agents and the development of nephrogenic systemic fibrosis in patients who have severe chronic kidney disease, our study supports the long-held belief that gadolinium based contrast agents can be used safely in both pediatric and adult patients with normal or with only mildly impaired renal function, said Dr. Richard Cohan, co-author of the study. The risk of allergic-like reactions is exceedingly low (0.07% of administrations in our study), and no fatal reaction occurred at our institution in more than 78,000 intravenous administrations. Patients should feel reassured, based on our results, that the intravenous gadolinium-contrast agents included in our study are quite safe when administered to patients with ample renal function, he said.

The full results of this study appear in the December issue of the American Journal of Roentgenology, published by the American Roentgen Ray Society.


'/>"/>
Contact: Necoya Tyson
necoya@arrs.org
703-858-4304
American Roentgen Ray Society
Source:Eurekalert

Related medicine news :

1. Role seen for cannabis in helping to alleviate allergic skin disease
2. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
3. New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
4. Protein suppresses allergic response in mice
5. Research finds allergic children exposed to peanuts at younger ages despite recommendations to avoid
6. London School of Hygiene to play key role in global collaboration on adverse drug reactions
7. DOCTORS OPPOSE MARYLAND VACCINE ROUNDUP: Expect Dangerous Reactions When Children Are Treated Like Cattle
8. MDs reactions to pharma marketing influenced by brand, side effects: Management Insights
9. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
10. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
11. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... The iaedp Foundation, the premier provider of ... for those suffering from the full spectrum of disordered eating, announced today that the ... from nearly all 50 states and several countries converged on the Green Valley Resort ...
(Date:3/24/2017)... CA (PRWEB) , ... March 24, 2017 , ... ... Ramin Assili, announce that they are now offering treatments for sleep apnea and ... at dental offices. Sleep apnea , specifically the obstructive type, is increasingly ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... the year of enhancements, upgrading their training and leads programs. , In February, ... Reserved for elite sales agents, Performance Partners is designed to teach how to ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... of inspiring stories about real people of God in congregations across the United ... Miller, a Presbyterian minister ordained in 1964 who has served congregations in seven ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... to their communities, 16 more public health departments have been awarded national accreditation ... another 4.5 million people into the expanding network of communities across the nation ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 24, 2017  GenomeDx Biosciences today announced that six ... Decipher® Prostate Cancer Classifier tests will be presented at ... (EAU) Congress held March 24 to 28, 2017 in ... Congress is Europe,s largest urological ... the urological field. The abstract titled "Muscle ...
(Date:3/24/2017)... BOTHELL, Wash. , March 23, 2017 /PRNewswire/ ... developer of advanced medical technology for non-invasive surgery, ... the Mirabilis System for treatment of uterine fibroids ... that it had received approval from the US ... study of the Mirabilis System in the United ...
(Date:3/24/2017)... Mar 24, 2017 The Board of Directors ... Annual Report 2016 including the complete 2016 Annual Accounts with ... on Nordic Nanovector,s website in the section Investor Relations/Reports and ... ... Tone Kvåle, Chief Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
Breaking Medicine Technology: